Methods for detecting and quantifying target species by metagenomics analysis

The method uses metagenomic analysis with a control species to verify and set detection thresholds, addressing the complexity of multiplex PCR and ensuring accurate detection and quantification of target species in samples.

JP7591554B2Active Publication Date: 2024-11-28BIOMERIEUX SA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022504011
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-23
Filing Date
2020-07-22
Publication Date
2024-11-28
Estimated Expiration
2040-07-22

AI Technical Summary

Technical Problem

Existing methods for detecting and quantifying multiple target species in a sample require prior knowledge and are complex, especially when using multiplex PCR, and metagenomic analysis lacks a reliable method to verify the correctness of biological and bioinformatic steps.

Method used

A method involving metagenomic analysis that includes sequencing nucleic acids, using a control species to verify the process, and setting detection thresholds to confirm or quantify target species presence, allowing for accurate detection and quantification without prior knowledge.

Benefits of technology

Enables reliable detection and quantification of target species by ensuring the integrity of metagenomic analysis steps and providing accurate results, improving specificity and sensitivity over traditional methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591554000011
    Figure 0007591554000011
  • Figure 0007591554000012
    Figure 0007591554000012
  • Figure 0007591554000013
    Figure 0007591554000013
Patent Text Reader

Abstract

The disclosed method is a method for detecting and quantifying a target species by metagenomics analysis. The method is a method for detecting a target species (SOI) present in an analytical sample, wherein the target species has a known genome, the analytical sample contains a mixture of various species, and the method comprises: a) extracting a diffusion sequence from an analytical sample; b) sequencing the nucleic acid sequences extracted in step a); c) obtaining normalized sequences assigned to the target species and the control species based on the sequencing; d) comparing the normalization sequences assigned to the target species and the control species, respectively, with detection thresholds associated with the target species and the control species, respectively.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The technical field of the invention is the identification of target species by metagenomic analysis. [Background technology]

[0002] The amplification of nucleic acids by polymerase chain reaction (PCR) allows for rapid and early diagnosis of the presence of a particular microorganism in a sample. PCR is particularly suitable for detecting deoxyribonucleic acid (DNA) of difficult-to-culture or slowly emerging bacteria, such as Mycobacterium tuberculosis.

[0003] However, performing PCR requires the use of primers that specifically target genes present in the target species. PCR therefore allows for a species-specific analysis, making it a sensitive and selective method that can be quantitative. However, this presupposes prior knowledge of the target species. When searching for several species, the process becomes more complicated, since so-called multiplex PCR must be performed.

[0004] It is also possible to target genes present in different target species. For bacteria, this may be a question of the 16S RNA gene for example. In that case, the PCR analysis is said to be broad-range. However, broad-range PCR is more difficult to perform and assumes that prior knowledge about the target species to be identified is available. Gene targeting is described in EP2985350 or in the publication by Stammler F. “Adjusting microbiome profiles for differences in microbiome load by spike-in bacteria”, Microbiome (2016) 4, 28.

[0005] In contrast to the above mentioned techniques, metagenomics allows sequencing the genomes of multiple individuals of different biological species in a given medium. It is possible to determine which species are actually present in the sample and their relative abundance. Metagenomics sequences the genomes of multiple individuals of different species in a given medium and does this without prior knowledge of whether the biological species in the sample are bacterial, viral or human. In this way, an analysis of the various genomes of the biological species in the sample is obtained. It is then possible to determine which species are present and their relative abundance.

[0006] Recently, progress has been made in the field of sequencing, and second and third generation sequencing techniques are called HTS techniques, where HTS stands for high-throughput sequencing. Improved bioinformatics capabilities have been achieved, allowing rapid computational processing of the biological information generated by sequencing. At the moment, high-throughput sequencing can generate enough sequences to obtain a representative inventory of the various species present in a sample. It is a commercially available analytical method, and its use has become relatively common. Document WO2018 / 069430 describes the application of metagenomic analysis to the identification of pathogens and markers of resistance to antibiotics.

[0007] The publication by Ruppe E "Clinical metagenomics of bone and joint infections: a proof of concept study" also describes the application of metagenomics to bacterial identification. The publications WO2017 / 053446 and Schlaberg "Validation of metagenomic next-generation sequencing tests for universal pathogen detection" describe metagenomic methods for analyzing samples, where an internal control formed by a known biological species is introduced into the sample. Summary of the Invention [Problem to be solved by the invention]

[0008] The present inventors provide a method for detecting and potentially quantifying a target species or a range of target species in a sample by performing metagenomic analysis of the sample, which in addition can establish an indication as to whether the biological or bioinformatic steps of the metagenomic process are proceeding correctly. [Means for solving the problem]

[0009] One subject of the present invention is a method for detecting a target species potentially present in an analytical sample, said target species having a known or partially known genome and said analytical sample comprising a mixture of different species, said method comprising: a) extracting nucleic acid from said analytical sample; b) sequencing the nucleic acid sequences extracted in step a); c) Based on the results of the sequencing, (i) assigning the sequence obtained from step b) based on a sequence reference database; (ii) determining the amount of sequences assigned to the target species; (iii) taking into account the detection thresholds relevant to the target species; (iv) comparing the amount obtained from substep (ii) with said detection threshold considered in substep (iii), Prior to step a), a control species is added, said control species being added to the analysis sample at a known concentration, said control species having a known genome; and step c) comprises: (v) determining the amount of sequence assigned to said control species; (vi) taking into account the detection threshold associated with the control species; (vii) comparing the amount obtained from sub-step (v) with the detection threshold considered in sub-step (vi), d) determining the presence of said target species in the sample using the comparison made in sub-steps (iv) and (vii).

[0010] The method can include considering a decision threshold, and step d) can then include confirming or not confirming the presence of the target species above or below the decision threshold depending on the comparison made in substeps iv) and vii).

[0011] The decision threshold is preferably expressed in units corresponding to the number of sequences per unit volume (or unit weight), for example, genome equivalents per mL. The decision threshold varies depending on the target species.

[0012] Preferably, in substeps (ii) and (v), the amount of sequences assigned to the target species and the control species, respectively, is normalized with a reference amount, which may be, for example, the total number of sequences generated during sequencing.

[0013] In step d), If the amount of the sequence assigned to the control species is higher than the detection threshold associated with the control species, and the abundance of the sequence assigned to the target species is higher than the detection threshold associated with the target species; Step d) involves confirming the presence of the target species in the analytical sample. Thus, step d) may involve estimating the concentration of the target species.

[0014] According to one embodiment, the method preferably comprises, prior to step a), spiking the analysis sample with a calibrator having a known genome at a known concentration. In step d), estimating the concentration of the target species comprises: determining a first ratio between the amounts of sequences assigned to the target species and the calibrators, respectively; determining a second ratio between the genome sizes of the calibrator and the target species; - taking into account the concentration of said calibrator added to said analytical sample.

[0015] Estimating the target species includes calculating the product of the first ratio multiplied by the second ratio and the concentration of the calibrator added to the analytical sample.

[0016] The control species may act as a calibrator. In this case, in step d), estimating the concentration of the target species comprises: determining the ratio between the detection threshold of the target species and the amount of sequences assigned to the control species; determining the size ratio between the genome sizes of the control species and the target species; This may involve considering the concentration of a control species added to the analytical sample.

[0017] Estimating the concentration of the target species may then include calculating the product of the first ratio multiplied by the second ratio and the concentration of the control species added to the analytical sample.

[0018] Alternatively, estimating the concentration of the target species may include determining the coverage of the target species and the control species and calculating a ratio between the determined coverages, which may be multiplied by the concentration of the control species.

[0019] In step d), If the amount of the sequence assigned to the control species is higher than the detection threshold associated with the control species, and the abundance of the sequence assigned to the target species is below the detection threshold associated with the target species; Step d) is - Estimate the minimum detectable concentration of the target species; comparing a minimum detectable concentration of the target species with a decision threshold, and if the minimum detectable concentration of the target species is lower than the decision threshold, it may be presumed that the target species is not present in the analytical sample at a concentration higher than the decision threshold.

[0020] Next, estimating the minimum detectable concentration of the target species is determining a first ratio between a detection threshold for the target species and an amount of sequence assigned to the control species; determining a second ratio between the genome sizes of the control species and the target species; This may involve considering the concentration of a control species added to the analytical sample.

[0021] In step d), if the amount of the sequence assigned to the control species is lower than the detection threshold associated with the control species; and the amount of the sequence assigned to the target species is higher than the detection threshold associated with the target species, Step d) comprises comparing the concentration of the control species added to the analytical sample with the decision threshold; Step d) is determining that the target species is present in the analytical sample at a concentration greater than the decision threshold if the concentration of the control species added to the analytical sample is greater than the decision threshold; determining that the target species is present in the assay sample if the concentration of the control species added to the assay sample is lower than the decision threshold.

[0022] In step d), if the amount of the sequence assigned to the control species is lower than the detection threshold associated with the control species; and the amount of the sequence assigned to the target species is below a detection threshold associated with the target species, The presence of said target species cannot be confirmed. Steps a) to c) are considered invalid.

[0023] The method includes a prior step of determining a detection threshold associated with the target species using a first plurality of training samples deemed not to contain the target species, The method includes, for each first training sample: Extracting nucleic acid sequences; - sequencing the nucleic acid sequences thus extracted; determining the amount of target sequences assigned to said target species; optionally normalizing the amount of said target sequence assigned to said target species, The method comprises: calculating a variance indicator of the amount of the target sequence or the normalized amount of the target sequence determined for each first training sample; determining a detection threshold associated with said target species as a function of the dispersion indicator thus calculated.

[0024] The method may include calculating the average or median of the target sequence determined for each first training sample, optionally normalized, amount.The detection threshold associated with the target species is then also determined according to the average or median.

[0025] The method includes a prior step of determining a detection threshold associated with the control species using a second plurality of training samples deemed not to include the control species; The method further comprises: for each second training sample: Extracting nucleic acid sequences; - sequencing the nucleic acid sequences thus extracted; determining the amount of sequence assigned to said control species; optionally normalizing the amount of sequence assigned to said control species; The method comprises: calculating a variance indicator of the amount of sequences or normalized amount of sequences determined for each second training sample assigned to said control species; determining a detection threshold associated with said control species as a function of the dispersion indicator thus calculated.

[0026] The method may include calculating the average or median of the amount of the optionally normalized sequence assigned to the control species and determined for each second training sample.The detection threshold associated with the control species is then also determined according to the average or median.

[0027] Each second training sample may be an analytical sample to which no control species is added.

[0028] Generally, the normalized amount of sequences is obtained by dividing the amount of sequences obtained from sequencing by a reference amount, which may be the total number of sequences generated during sequencing.

[0029] According to one embodiment, steps c) and d) are performed in parallel for different target species, each of which is considered as potentially present in the sample, and according to one such embodiment, steps c) and d) are performed for each target species.

[0030] According to one embodiment, the method comprises, prior to step a), adding a plurality of said control species, and for a given target species, steps c) and d) are carried out taking into account a plurality of said control species, and sub-steps iv) to vi) are carried out in parallel for each said control species.

[0031] Other advantages and features will become more apparent from the following description of particular embodiments of the invention, which are given as non-limiting examples and are illustrated in the figures listed below. [Brief description of the drawings]

[0032] [Figure 1] FIG. 2 shows a schematic diagram of the main steps of the method according to the invention;

[0033] [Figure 2A] FIG. 1 shows a comparison of the quantification of the target species, in fact S. aureus, obtained by carrying out the steps described below (y-axis) and the reference method using culture (x-axis), respectively.

[0034] [Figure 2B] FIG. 1 shows a comparison of the quantification of the target species, namely S. aureus, obtained by carrying out the steps described below (y-axis) and a reference method using quantitative PCR (x-axis), respectively.

[0035] [Diagram 3] FIG. 1 shows the statistical distribution of normalized sequence abundances corresponding to various target species, respectively, measured in training samples considered to not contain the target species.

[0036] [Figure 4] FIG. 1 shows a comparison of concentrations of target species estimated by culture (x-axis) and metagenomic analysis (y-axis), respectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0037] The aim of the method is to be able to detect the presence of a target biological species of interest (SOI) in a sample, in which case the method may allow absolute quantification of the target species SOI, so as to allow comparison with a decision threshold SD.

[0038] By biological species is meant a microorganism, such as a bacterium, a virus, a fungus, an archaea, an amoeba, a protist, or a microalgae. A biological species may also be a cell or any other object or entity that contains a sequence of nucleic acid.

[0039] If the sample is obtained from a human or animal organism, the target species may be a pathogenic species. If the sample is obtained by industrial methods or environmental sampling, the target species is a species that is considered to be a contaminant or a target species of importance in an industrial process or environment, the presence or concentration of which it is desired to determine.

[0040] The target species has a known or partially known genome, or a known segment of the genome, which consists of sequences referred to as target sequences.

[0041] The method is capable of treating multiple target species simultaneously, and thus the term "target species" should be interpreted as meaning at least one target species.

[0042] The decision threshold SD is a threshold value that allows characterizing the load of a target biological species, for example a microorganism, depending on the intended application. It is set, for example, in the light of regulatory or sanitary or industrial limits. For example, when used to support clinical diagnosis, if the target biological species is a bacterium, the decision threshold may be a concentration below which the presence of bacteria corresponds to colonization, i.e. a non-pathological appearance, and above which the presence of bacteria is considered to be pathological, for example an infection. When the invention is applied to industrial processes, the detection threshold corresponds to a pass value, above which the sample is considered to be unsuccessful and below which the sample is considered to be passed. Whatever the application, if the concentration of the target biological species is equal to or greater than the decision threshold, the species is defined as important. If the concentration of the target biological species is lower than the decision threshold in a particular application, for example in the production of fermentation products, the concentration corresponding to the minimum acceptable concentration of the species is considered to be important.

[0043] The sample is generally a sample sampled from the environment, or from a dead or living organism, or even from a manufactured product or a product related to food production. Samples may also be obtained from industrial facilities for step control. Thus, the sample includes various species that do not have the same genome. In particular, when the sample is obtained from a sample acquisition of an organism, for example a human or animal organism, the sample will include a significant amount of cells from the sample organism, and these cells will likely constitute the majority of the sample. Human and animal genomes are 1000 to 100 000 times larger than the genomes of prokaryotes. In addition, the sample generally includes species that naturally occur in the sample and are unlikely to cause pathology or significant contamination. For example, if the sample is a bronchoalveolar sample, it will include the bacterial flora naturally occurring in the lungs. If the sample is a stool sample, it will include the bacterial flora naturally occurring in the digestive tract. Thus, if the target species is a bacterium or a virus, the nucleic acid of the target species may be a minority of the nucleic acid in the sample.

[0044] The sample contains what may be called "matrix" species that are endogenous to the sample and tend to mask metagenomic information related to the target biological species. For example, if the sample is obtained from yogurt, meat or a vaccine, the sample contains matrix species representative of these media. In the case of a sample obtained from an organism, the matrix contains the constituent cells of the organism.

[0045] One important aspect of the invention is that the sample undergoes extraction of nucleic acids (DNA and / or RNA) followed by a sequencing process, according to the principles of metagenomic analysis. The sequencing process may be preceded by an amplification process. The sequencing may be Whole Genome Sequencing (WGS), and in particular Whole Genome Shotgun Sequencing. In this way, an inventory of the sequences of the genes of the various species of the sample is obtained. All or almost all of the nucleic acids of the various species of the sample are sequenced using high-throughput sequencing. Bioinformatic means then make it possible to identify target sequences associated with the target species and to determine their amount, generally their normalized amount, as described below. The bioinformatic means are based on a database of reference sequences, for example a complete reference genome in the context of the WGS process as described above. The database comprises at least all or part of the genome of the target species potentially present in the sample. It also comprises all or part of the genome of a species called control species, the latter of which is described below.

[0046] Thus, with this technology, a description of the genomes of the various species in the sample is obtained by sequencing. Among the inventoried genomic sequences, sequences corresponding to the target species and sequences corresponding to the control species are then identified.

[0047] The method includes the steps described below with reference to FIG. Step 10: Take the sample. In this example, samples are obtained from a living human organism to aid in diagnosis, but the invention is not limited to application in the field of living organisms. Samples can be obtained from industrial or hospital environments to verify suitability with respect to the decision threshold. Step 20: Add a control species.

[0048] One of the objectives of the present invention is to evaluate the extent to which metagenomic analysis is usable. It is in particular a question of evaluating the suitability of all steps from sample preparation, except for sampling, to the bioinformatic analysis of the sequencing data. For this purpose, a control species, called SPC, an acronym for sample processing control, is added to the sample. One function of the control species is to make it possible to check whether the steps of extracting nucleic acids and of sequencing, described below, are proceeding correctly. The control species SPC may be a known biological species, the genome of which may also be known, preferably in its entirety. The control species SPC may be a natural biological species. It may also be an artificial species, for example an encapsidated RNA (ribonucleic acid). Preferably, the control species SPC is not initially present in the sample or, if present, is present in a negligible amount. Preferably, the content of the control species SPC initially present in the sample, i.e. before addition, is determined by the concentration C of the control species SPC added to the sample. SPC Preferably at least 10-fold, preferably at least 100-fold or 1000-fold lower than the control species SPC. The control species SPC may for example be a bacterium. It is important to control the concentration of the added control species.

[0049] The control species can be selected taking into consideration the following: a) The control species should preferably be distinct from the naturally occurring or endogenous organisms in the sample and from the target species, so that bioinformatic tools can accurately identify sequences generated by sequencing of the SPCs. b) The amount of sequence assigned to the control species during sequencing must be sufficient to allow accurate detection without masking the useful information corresponding to the sequence of the target biological species. In other words, the control species is preferably not predominant in the sample, but is detectable by high-throughput sequencing. In particular, when it is desired to determine positive (concentration of species above decision threshold) or negative (concentration of species below decision threshold), it is preferred that the control species is as follows: The size of its genome is preferably similar or at least comparable to the size of the genome of the target species. More particularly, the size of the genome of the control species is comprised between 0.1 and 10 times the size of the genome of the target species. Control species concentration C SPC may be set according to a decision threshold. The concentration C of the added control species SPC SPC may include, for example, 0.001 to 1000 times, preferably 0.01 to 100 times, the decision threshold. The nucleic acid of the control species SPC is subjected to the same treatment as the nucleic acid of the target species in the sample preparation, extraction and sequencing steps, preferably The percentage of GC (guanine, cytosine) bases is preferably close to the percentage of GC bases of the target species, where close means 75% to 125%, preferably 80% to 120%. The control species preferably comprises an intact cell wall or membrane if the target species is a bacterium, or a protein shell if the target species is a virus. This condition further makes it possible to monitor the step of lysis or extraction of the nucleic acid of the target species. c) Preferably, the nucleic acid sequence of the control species does not contain genomic markers, such as markers of resistance to antibiotics, or pathogenicity markers, so that the results of a potential test for susceptibility to antibiotics are not destroyed by the presence of such markers in the genome of the target species. Preferably, the nucleic acid sequence of the control species does not contain other genes of clinical or industrial interest, the presence of which is easily checked. d) The control species is preferably easily manipulable, in particular -Harmless to humans and the environment; - and / or is resistant to heat treatments such as freeze-drying and freezing, making it easy to store. e) The control variety must not produce spores, and if it does produce spores it should be very little. f) The control species must have a lytic susceptibility similar to that of the target species. g) The control species is available in the form of balls, each ball containing a calibrated concentration of the control species in lyophilized form.

[0050] It should be noted that a single control species SPC may be used or multiple control species of different types may be used. Different control species may be used for a given target biological species. According to one possibility, the control species forms a calibrator. According to another variant, a calibrator different from the control species is added to the sample. The calibrator makes it possible to estimate the concentration of the target species in question. This alternative, which corresponds to a variant of the invention, is explained after the description of steps 61 to 64. See the section entitled "Variants".

[0051] Addition concentration of control SPC C SPC is preferably known accurately. Specifically, if certain conditions are met, the concentration of the target biological species in the sample can be quantified, and then the control species forms the calibrator. The term spike concentration refers to the concentration of the control species in the sample by the addition of the control species.

[0052] In the description of steps 30 to 60, the addition of a single type of control species to the sample is advantageously described. The control species then performs the functions of quality control and calibrator in the metagenomic analysis steps and allows quantification of the concentration of the target biological species.

[0053] At the end of step 20, the control species concentration C SPC is added to the sample. The added concentration C SPC can be expressed in GEq / mL (genome equivalent per mL). Step 30: Lysis and extraction of nucleic acids. In this step, the cells of the sample, particularly the target and control species, are lysed to allow the DNA to be extracted. Different strategies can be envisaged. Lysis can be parameterized to preferentially target target species. The control species must have the same or comparable lytic susceptibility as the target species. Lysis may include a first lysis intended to essentially lyse cells other than the target species. Such a first lysis may be envisaged, for example, when the target species is very few in number relative to the cells of the matrix in the sample. The first lysis is followed by removal of the released nucleic acids and then a second lysis targeted to the target species. In such a scenario, the control species is preferably resistant to the first lysis and not to the second lysis.

[0054] Following lysis, DNA is extracted from the sample using, for example, the extraction methods described in WO2014 / 114896.

[0055] The DNA extracted from the sample may essentially consist of the DNA of the matrix, i.e., the DNA of the environment from which the sample was obtained. In this case, the sample is subjected to selective capture and / or amplification, targeting sequences and / or physicochemical modifications that are specific to the genome of the target organism. In this case, the control species contains the sequences and / or physicochemical modifications that are targeted by selective capture or amplification. Conversely, the sample may be subjected to depletion that essentially targets the DNA of the matrix. In this case, the control species does not contain any of the sequences or physicochemical modifications that can be targeted by depletion. Step 40: Amplification and sequencing.

[0056] After extraction of DNA, the DNA fragments can be optionally amplified in a targeted manner, for example via polymerase chain reaction (PCR), or in a non-targeted manner, for example via whole-genome amplification (WGA). The DNA extracted from the sample is amplified, if appropriate, and subjected to sequencing, preferably whole-genome sequencing (WGS). There are many sequencing techniques, for example sequencing by synthesis (SBS), or nanopore sequencing, or sequencing by hybridization. Whatever technique is used, the goal of sequencing is to provide digital nucleic acid sequences, called reads. Sequencing involves the preparation of a sequencing library (library preparation), optionally followed by an amplification step, and then the actual sequencing step. The techniques used to sequence nucleic acids are well known and will not be described in detail. Amplification and sequencing can be carried out using the platform MiSeq, sold by the company Illumina.

[0057] During the preparation of a sequencing library, the DNA can be randomly split to obtain nucleic acid sequences of a target average length, generally consisting of an average length of 50 bases to 300 bases. Referred to as shotgun sequencing or whole genome sequencing (WGS). In this type of technique, the nucleic acids, whatever their origin, are treated similarly during the preparation of the sequencing library.

[0058] Following the preparation of the sequencing library, high-throughput sequencing is performed. The sequencer reads the bases of the sequenced DNA fragments and obtains sequences called reads. Each read corresponds to one sequence decoded by the sequencer. The sequences generated by sequencing are then aligned with respect to genomes stored in a database, including in particular the genome of the target organism species and the genome of the control species. Sequencing is an operation known to those skilled in the art. Details related to sequencing operations are described, for example, in the documents cited in the prior art, in particular WO2018 / 069430 or the publication by Ruppe E cited above.

[0059] The sequencer transmits a file containing the reads, corresponding to the measurements performed, to a data processing unit. The latter comprises a memory in which are stored instructions that allow the implementation of sequencing algorithms. The sequencing algorithms make it possible to identify, for each sequence, the genome that constitutes the sequence among the several genomes stored in the database. They also establish the position of each sequence in the genome to which it belongs, making it possible to assemble the various sequences belonging to a given genome.

[0060] At the end of step 40, sequencing data on the various biological species of the sample are obtained. It is in particular a matter of the identity of each species and the amount of sequences assigned to each identified species. In particular, the number of sequences assigned to the target biological species R SOI and the number of sequences assigned to the control species, R SPC is obtained. Step 45: Identification of the species to which the lead belongs.

[0061] In this step performed by the data processing unit, the origin of each read is identified with respect to a bacterial species. This step is commonly known as binning or taxonomic binning or assignment and involves comparing each read to a digital nucleic acid sequence in a reference database. For example, Kraken, (Wood and Salzberg, "Kraken: ultrafast metagenomic sequence classification using exact alignments", Genome Biology, 2014), or "Wowpal Wabbit" (Vervier et al., "Large-scale machine learning for metagenomics sequence classification", Bioinformatics, 2015), or "BWA-MEM" (Li, "Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM", Genomics, 2013) are known binning software packages. If the read is completely contained in a genome representing the target species stored in the database, the read is preferably assigned to the target species. Step 50: Normalization.

[0062] The amount of sequencing data obtained from step 45 is not the same for all samples. In particular, the number of sequences generated by sequencing depends on the quality and quantity of DNA of the various constituent biological species of the sample. It is therefore preferable or even necessary to normalize the amount of sequences associated with a species with respect to a reference amount. The normalization depends on the type of sample analyzed and the metagenomic analysis applied. The reference amount can be, for example, the total number of sequences generated for the analyzed sample. The normalized amount of sequences associated with each species, i.e. the amount divided by the reference amount, is 1. EMultiplied by 6 to get the normalized quantity corresponding to reads per million (RPM).

[0063] According to other variants, the reference amounts can be, non-exhaustively: The reference quantity is the total number of sequences associated with all identified microorganisms. The reference quantity is the total number of sequences associated with the organism from which the sample was drawn. For example, if the organism is the human body, the total number of sequences associated with the human genome may be determined. The reference quantity is the total number of sequences related to a reference species. By reference species is meant an endogenous or exogenous species that is believed to always be present in the various samples obtained. A reference species may be a control species. The reference quantity is the total number of sequences associated with a given species in a sample that does not contain the target species (negative sample) or in a buffer that does not contain the sample.

[0064] Step 50 is performed for the target species (or each target species) and the control species (or each control species SPC or each calibrator). In this way, a normalized quantity RN SOI is obtained, and for the control species SPC (or each control species or each calibrator) a normalized quantity RN SPC In the notation RN, the letter N indicates that the quantity is normalized.

[0065] In the following, and without limitation, it is assumed that there is only a single target species and a single control species. In the remainder of the specification, the term "amount" may refer to a normalized amount. Step 60: Interpretation.

[0066] This step is a critical step of the present invention: it is a question that determines to what extent the sequencing results are interpretable.

[0067] This step involves determining the detection thresholds DT SOI and D.T. SPC The detection thresholds can be set based on the statistical detection thresholds determined for the target biological species and the control species, respectively. The statistical detection thresholds are set in advance in step 100, which will be described later. In general, the statistical detection threshold corresponds to the lowest value of the analyte concentration measured using the detection method, which is statistically different from the concentration measured under the same conditions if the analyte is not present in the sample. Each detection threshold may be equal to the statistical detection threshold or determined based on the statistical detection threshold, in particular k times equal to the statistical detection threshold, where k is a real number other than 0.

[0068] The purpose of interpretation is to determine the normalized quantity RN of the sequence. SOI and R.N. SPC The method involves assigning the sequence of interest to a target species SOI and a control species SPC, respectively, and comparing them to their respective detection thresholds. Specifically, if the normalized abundance of the sequence assigned to the target species is equal to or greater than its associated detection threshold, the target species can be considered detected with an acceptable confidence level. Similarly for the control species. The comparison distinguishes between four situations: ·RN SOI ≧ DT SOI And RN SPC ≧ DT SPC :See step 61 ·RN SOI ≧ DT SOI And RN SPC < DT SPC :See step 62 ·RN SOI < DT SOI And RN SPC ≧ DT SPC :See step 63 ·RN SOI < DT SOI And RN SPC < DT SPC :See step 64 Step 61: Quantification

[0069] RN SOI ≧ DT SOI And RN SPC ≧ DT SPC If the concentration of the target species SOI is C, then the detection of the target species and the control species is confirmed. The target species SOI is considered to be present in the sample with a sufficient confidence level. SOI can be estimated based on the following: The concentration C of the control species SPC added to the sample following step 20 SPC . The arbitrary normalized quantity R of sequences assigned to the control species SPCs obtained from step 45 SPC . The number of sequences assigned to the target species, R, obtained from step 45 SOI。 Genome size data for the control and target species.

[0070] For example, the following formula can be used: TIFF0007591554000001.tif10150, where L SPC and L SOI are the genome lengths of the control and target species, respectively. α is a correction factor that is empirically determined based on training samples with known concentrations of the target species. The correction factor α allows taking into account differences in the efficiency of the sequencing process for the target and control species. By default, α is set to 1 (α=1). This unit value provides sufficient absolute quantification to determine a sample as positive or negative relative to the decision threshold.

[0071] When spiked concentrations are expressed in GEq / mL, the concentrations of the target species are also expressed in the same units.

[0072] Alternatively, sequencing involves assembling sequences associated with the control and target species, respectively, and determining the coverage, Cov, of the assembly for each species. The concentration, C, of ​​the target species is then determined. SOI can be calculated using the following formula: TIFF0007591554000002.tif10150, where Cov SPC and Cov SOI are the coverages determined for the control and target species, respectively. Coverage refers to the average number of times a base has been sequenced at a particular position in the genome, as described in Lacoste C et al. “Le sequencage d´ADN a haut debit en pratique clinique” [High-throughput DNA sequencing in clinical practice], Archives de Pediatrie 2017, 24, 373-383. ·α' is a correction factor that is empirically determined based on training samples with known concentrations of the target species. The correction factor α' allows to take into account differences in sequencing efficiency between the target and control species. By default, α' is set to 1 (α'=1). This unit value provides sufficient absolute quantification to determine a sample as positive or negative relative to the decision threshold.

[0073] According to one variant described below, step 61 may be performed with a species different from the control species and forming a calibrator. In this case, the control species is used in step 60 to confirm the detection of the target species and step 61, i.e. the quantification, is performed using a calibrator, the latter being used only for the quantification. The properties of the calibrator are preferably similar to those of the control species and correspond to those described with reference to step 20. The quantification using the calibrator can be performed using formula (1) or formula (1'). Formula (1) is as follows: TIFF0007591554000003.tif10150, where ·R CAL is the number of any normalized sequence assigned to the calibrator. L CAL is the length of the calibrator genome. C CAL is the concentration of calibrator added to the sample. α is the correction coefficient explained with reference to equation (1).

[0074] Equation (1') becomes: TIFF0007591554000004.tif10150Cov CAL is the coverage determined for the calibrator. α is the correction coefficient explained with reference to (1'). Step 62:

[0075] RN SOI ≧ DT SOI And RN SPC < DT SPC This means that the control species is not detected, but the target species is considered to be detected. However, the target species cannot be quantified with sufficient confidence. This step is performed by adding the control species to the spiked concentration C SPC and a decision threshold SD. C SPC If < SD, no information is available regarding the concentration of the target species relative to the decision threshold. C SPC If ≥ SD, the concentration of the target species cannot be estimated but can be considered to have exceeded the decision threshold. The concentration of the target species cannot be quantified but it can be concluded that the decision threshold has been exceeded. Step 63:

[0076] RN SOI < DT SOI And RN SPC ≧ DT SPCIf so, the sequencing can be considered to have worked correctly. This step involves estimating the minimum detectable concentration of the target species. SOI corresponds to the minimum concentration that can be distinguished from background noise. It is the detection threshold DT SOI The minimum detectable concentration can be determined based on: The concentration C of the control species SPC added to the sample following step 20 SPC . The number of sequences assigned to the control species SPCs obtained from step 45, R SPC . Detection threshold DT associated with the target species SOI . Genome size data for control and target species. TIFF0007591554000005.tif10150, where L SPC and L SOI are the genome lengths of the control species SPC and the target species SOI, respectively. α is the correction coefficient explained with reference to equation (1).

[0077] Step 63 determines the decision threshold SD as the minimum detectable concentration Cmin SOI This includes comparing with. ·Cmin SOI If ≦SD, the detection of the target species can be considered negative: the concentration of the target species in the sample is below the decision threshold. ·Cmin SOI > SD, the decision threshold does not provide any information about the presence and concentration of the target species in the sample. Step 64:

[0078] RN SOI < DT SOI and R.N. SPC < DT SPCIn some cases, lack of detection of a control species SPC suggests that the assay has not achieved the required performance for detection of the target species. The assay cannot be interpreted. The assay may be considered invalid. Such situations may arise when: One of the sequencing steps does not achieve the performance required to detect the target species. and / or if the sample contains a large amount of DNA from the patient or matrix or flora. and / or if the sample contains a high concentration of at least one species, which generates a large number of sequences, which has the effect of masking other target sequences.

[0079] Upon completion of one of steps 61 through 64, confirmation of the presence of the target species at a concentration above the decision threshold, and quantification, if any, is used to aid in diagnosis. Variations

[0080] In the above described embodiment, the control species SPC performs both the function of quality control of the metagenomic analysis and the function of a calibrator, allowing for the quantification of the target biological species in the sample.

[0081] According to one variant, a control species SPC and a calibrator different from the control species are added to the sample. It is for example a matter of two different bacterial species. The control species SPC performs a function related to the control of the quality of the metagenomic analysis. The calibrator allows to quantify the target biological species in the sample according to formula (1) or (1') or (2). If the calibrator is different from the control species, it preferably has the same properties as the control species, these properties being explained with reference to step 20. The control species SPC is added at a first concentration. A detection threshold is assigned and step 60 is carried out by comparing the amount of normalized sequences assigned to the control species, obtained from step 50, with the detection threshold associated with the control species. The calibrator is also added to the sample at a second concentration. A detection threshold is assigned. In step 61, the quantification can be performed taking into account the amount of normalized sequences associated with the calibrator and the detection threshold associated therewith.

[0082] Calibrators may be added before lysis, or after lysis and before sequencing.

[0083] In another variant, multiple calibrators are added to the sample, each calibrator being selected for one or more target species. In particular, groups of bacterial species may react substantially differently to the process of extracting nucleic acids (e.g., gram-positive and gram-negative bacteria). Advantageously, if one or more target species are gram-positive, a calibrator consisting of gram-positive bacteria is added, and if one or more target species are gram-negative, a calibrator consisting of gram-negative bacteria is added. Similarly, the target species may be composed of bacteria and viruses. In this case, the first calibrator is bacterial and the second calibrator is viral. The auxiliary one is viral. In general, in the steps of sample preparation (extraction, optionally sequence library preparation or amplification and sequencing), it is a question of selecting calibrators that behave as similarly as possible for the target species to be calibrated. Step 100: Setting the detection threshold.

[0084] As mentioned above, it is necessary that each control species and target species is associated with a detection threshold. For a given species (control or target species), the detection threshold is set prior to the interpretation of the results using training samples that do not contain that species. It is a matter of samples that are negative for the species in question. These samples are representative of the analyzed samples. Typically, this means that these training samples contain a population of species comparable to that of the analyzed samples, both qualitatively and quantitatively. The absence of the target species and / or control species in each training sample can be confirmed using standard culture and / or PCR-based methods.

[0085] On each training sample, sequencing is preferably carried out under the same conditions as described with reference to steps 30 to 45. Following sequencing, the amount of sequence assigned to the species in question is determined. This amount is preferably normalized as described with reference to step 50.

[0086] Thus, the detection thresholds associated with the target species and the control species, respectively, can be established using a first training sample that does not include the target species and a second training sample that does not include the control species, respectively. The first training sample can be none other than the second training sample, and vice versa. In that case, the detection thresholds associated with the target species and the control species are determined with the same training sample.

[0087] Sequencing is preferably performed on a statistically representative number of training samples. This results in a statistical distribution of normalized sequence amounts. The mean μ and a dispersion indicator of the distribution, such as the standard deviation σ or variance σ, are then calculated. 2The detection threshold is estimated by adding the mean μ to the variance indicator n times (n is a real number), where n is typically between 2 and 4.

[0088] Since the detection thresholds associated with the target and control species, respectively, are intended to be compared with normalized amounts of the target and control species sequences, it is important that the normalization performed in step 100 is similar to the normalization performed in step 50.

[0089] The above steps can target multiple target biological species simultaneously. Moreover, this is a notable advantage of metagenomic analysis, which can address various biological species simultaneously. Another advantage of metagenomic analysis is that multiple control species can be used simultaneously. Thus, one control species can be used to target one or more biological species, while another control species can be used to target other target biological species. This is another advantage of metagenomic analysis.

[0090] It is even conceivable to use several control species for a given target species. For example, steps 61 to 64 can be carried out using various control species for a given target species. This can limit the risk of the method failing due to defective sequencing of the control species. Estimates regarding the presence of the target species with respect to the decision threshold are obtained for various (species, control species) pairs. If several control species are used for a given target species, it is possible to obtain several quantifications according to formula (1), (1'), in which case the mean or median of the obtained quantifications, or the quantification considered to be the most unfavourable, i.e. the quantification leading to the highest concentration of the target species or more generally the concentration closest to the decision threshold, can be taken into account.

[0091] More generally, metagenomic analysis still requires powerful computational tools. In contrast, it allows a degree of operational flexibility in that it allows multiple species (and / or multiple control species) to be addressed simultaneously, the only condition being that the genome of the desired species and the genome of the respective control species must be known.

[0092] Steps 61 to 64 are performed by a computing unit, for example a microprocessor, based on the sequencing data generated in steps 40, 45 and 50 and delivered by the processing unit. In this way, sequencing data corresponding to the measurement data obtained from the analysis sample are transmitted via a wired or wireless link to the computing device, which performs one of steps 61 to 64. The microprocessor is connected to a memory containing instructions enabling steps 61 to 64 to be performed. Example 1

[0093] In a first example, Bacillus subtilis was verified to be a good candidate for use as a control species in metagenomic sequencing of samples obtained from bronchoalveolar lavage (BAL) performed on human patients. Since the patients are human, this type of sample is expected to contain a large amount of human DNA.

[0094] Metagenomic sequencing of such samples makes it possible to aid in the diagnosis of hospital-acquired pneumonia for diagnostic purposes. The clinical decision threshold was set at 1.0 E4 CFU / mL. CFU is the acronym for colony forming unit.

[0095] To remove the patient's DNA, the analysis protocol included a preliminary lysis to remove the patient's DNA. In a first lysis, the samples were treated with a lysis agent that specifically targets the patient's cells. Such lysis agents are described, for example, in WO2014 / 114896. The released DNA was then removed by enzymatic action and washing. The samples then underwent a second mechanical and chemical lysis to extract the bacterial DNA.

[0096] Provision was made in the protocol to add a control species to the sample before the lysis step. The species forming the control species had to be resistant to the lysis of human cells and sensitive to the lysis of bacterial cells. Some bacteria, especially gram-positive bacteria, are known to be difficult to lyse. Therefore, a species with a lysis resistance equivalent to that of gram-positive bacteria was selected as the control species.

[0097] Furthermore, the metagenomic sequencing performed was aimed at detecting and potentially quantifying approximately 20 target species of bacteria from the following list: Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Hafnia alvei, Klebsiella oxytoca, Klebsiella pneumoniae, Legionella pneumophila, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Stenotrophomonas maltophilia and Streptococcus pneumoniae.

[0098] The control species SPCs also had to be sequenced with an efficiency comparable to that of the target species mentioned above. It is known that sequencing efficiency is fundamentally dependent on the genome size and GC (guanine-cytosine) content. Thus, in this example, the genome size of the control species had to be between 1.9 and 6.6 megabases and the GC content had to be between 33% and 66%. Furthermore, the concentration of the control species added to the samples was set to 1.0 E4 CFU / mL, i.e., a concentration comparable to the decision threshold mentioned above.

[0099] The inventors have evaluated the desirability of forming control species using the following species: Bacillus stearothermophilus, Synechocystis sp. PCC6803, Pelagibacter ubique, Methanocaldococcus jannaschii, Aeropyrum pernix, Kocuria rhizophila, Azospirillum lipoferum, Lactococcus lactis, Synechococcus sp. WH 7805, Schizosaccharomyces pombe, Pantoea stewartii, Phage T4, Pichia pastoris, Armored DNA Quant TM and Bacillus subtilis.

[0100] Among these, Bacillus subtilis was found to have the necessary characteristics to be used as a control species. The genome size of Bacillus subtilis is 4.12 Mb (megabases) with a GC content of 43.6%. Bacillus subtilis is also commercially available in the form of "BioBalls"® - Biomerieux. These BioBalls are water-soluble balls containing a calibrated concentration of Bacillus subtilis, which allows the concentration of the added control species to be adjusted. Rehydration of BioBall MultiShot 550 in 600 μL of bronchoalveolar lavage sample corresponds to an added concentration of Bacillus subtilis equal to 9.2 E3 CFU / mL, which is close to the decision threshold of 1.0 E4 CFU / mL.

[0101] DNA extracts from samples containing fresh cultures of Bacillus subtilis and samples containing Bacillus subtilis were spiked in BioBalls and compared by real-time PCR. The PCR results were comparable.

[0102] Seven samples obtained by bronchoalveolar lavage (BAL) were sequenced without prior addition of Bacillus subtilis. In four of the seven samples, only a small number of sequences were observed to be assigned to Bacillus subtilis; it was less than 5 reads per million. Thus, the number of false positives was negligible. In the other samples, sequences were assigned to Bacillus subtilis as a result of sequence assignment software errors or as a result of the presence of sequences highly similar to those of Bacillus subtilis in the samples. However, the number of sequences assigned to Bacillus subtilis never exceeded 200 reads per million and was therefore relatively low.

[0103] Forty-six samples obtained by BAL were spiked with Bacillus subtilis at a concentration of 1.7 E4 CFU / mL, within the uncertainty range. After sequencing, the number of sequences assigned to Bacillus subtilis exceeded 1000 reads per million for 36 of the 46 samples.

[0104] This example shows that Bacillus subtilis is a species that is likely to form a control species in samples obtained by BAL, using the analytical protocol described at the beginning of the example. Example 2

[0105] This example describes the detection and quantification of Staphylococcus aureus in samples obtained by bronchoalveolar lavage (BAL) applying the dual lysis protocol described in Example 1 above and steps 10-50.

[0106] A cohort of 13 samples obtained by BAL was used. Based on the conclusions of Example 1, the control species used was Bacillus subtilis, which was added to each sample at a concentration close to the decision threshold (1.0 E4 CFU / mL). In this example, the control species was added to each sample in 1.1 mL of PBS buffer (PBS stands for phosphate-buffered saline) using a BioBall MultiShot 10 E 8 - obtained by rehydration of Bacillus subtilis ATCC 19659 (Biomerieux). The control species was diluted to 1.0 E6 CFU / mL in PBS and 10 μL was added to 600 μL of sample. A spike concentration of 1.7 E4 CFU / mL was obtained.

[0107] Each sample was processed up to 48 hours after obtaining the sample. Each sample underwent a first lysis specific for human cells as described above. Unlysed cells were pelleted and treated with DNase I. DNase I was inactivated by heating and adding EDTA (ethylenediaminetetraacetic acid) before extracting human DNA. Each sample was then subjected to a second lysis. This was performed by adding the sample to a bead stirring tube containing a mixture of glass beads with a diameter of 1 mm and Zr / Si beads with a diameter of 0.1 mm. Lysis was obtained by shaking the tube for 20 min. DNA was extracted from the lysate using the Biomerieux platform easyMAG®. Elution was performed in a volume of 25 μL. Extracts were stored at -20 °C.

[0108] Sequencing libraries for 2x250 paired-end reads were prepared using the Nextera® XT DNA Library Preparation Kit (Illumina). Samples were sequenced using the MiSeq® platform and the “MiSeq reagent kit V3” (Illumina).

[0109] The sequences were processed in a processing unit using the software package KRAKEN V0 10.5b and an internal sequence database. This database included, in particular, the sequences of the human genome and the sequences of the 20 target species described in Example 1. The number of sequences occurring in each sample varied between 331 000 and 17 000 000. The number of sequences related to the control species (Bacillus subtilis) and the target species (S. Aureus) was normalized to reads per million (RPM). In addition, a quantitative reference measurement was performed on each sample by quantitative PCR (qPCR) targeting the SpA gene. Amplification and real-time readout of the fluorescent signal was performed on the platform CFX96 Touch Real-Time PCR Detection System (Biorad).

[0110] Table 1 summarizes the sequencing results of the 13 culture-positive samples. Columns 1 to 7 correspond to the following: Refer to the sample. Quantification of S. aureus by culture. Quantification of S. aureus by qPCR. Normalized amount of sequences assigned to the control species (B. subtilis) SPC . Normalized amount of sequences assigned to the target species (S. aureus) SOI . If possible, the concentration of the target species, C, determined using equation (1) described in step 61 SOI Quantitative determination. If possible, the concentration of the target species, C, determined using formula (1') described in step 61 SOI Quantitative determination.

[0111] In this example, the control species SPC served as a calibrator in the sense that it was used in the quantification step.

[0112] SOI NA and SPC NA correspond to the fact that the number of sequences associated with the target species SOI and control species SPC, respectively, was insufficient to allow assembly. NA is an acronym for Not Assembled. [Table 1]

[0113] Samples 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 and 13 (12 of 13 samples) correspond to the configuration described with respect to step 61. For example, quantification of target species is possible according to equation (1) and equation (1').

[0114] Sample 8 corresponds to the configuration described with reference to step 64 and the results are not interpretable. Further investigation revealed that in this sample the sequence demultiplexing step had failed. This particular case is interesting as it shows that taking into account a control species can avoid the occurrence of "false negatives".

[0115] For the "quantifiable" samples (1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 and 13), the concentration C SOI was estimated using formula (1'). However, there were cases where sequences related to control species SPCs or target species SOIs were not assembled. In this case, the target species could not be quantified using this protocol, but was estimated using formula (1). This was especially the case for samples 2 and 13, where the amount of sequences related to the target species was insufficient to obtain an assembly and measure the sequencing depth. Therefore, quantification based on formula (1') is only possible if the amount of sequences is sufficient. Quantification based on formula (1) is preferred.

[0116] Figure 2A shows a comparison of quantification of S. aureus by culture (x-axis) and sequencing (y-axis). The correlation coefficients are low (r 2 = 0.2929). This low value can be explained by the imprecision of the culture method and the difference between the amount of viable and culturable cells detected by culture and the total amount of genome detected by sequencing. The particular patient from whom the sample was obtained had been treated with antibiotics, which tended to reduce the proportion of viable and culturable bacteria relative to the total bacterial count. Thus, culture provides only partial quantitative information.

[0117] Figure 2B shows the correlation between the quantitative results by meta-sequencing (Equation (1) - y-axis) and quantitative PCR (x-axis). The correlation coefficient is higher, r 2 = 0.9906, which indicates the reliability of quantification by meta-sequencing. Example 3

[0118] In this example, the detection of the 20 target pathogenic bacterial species described in Example 1 was tested in samples obtained by bronchoalveolar lavage (BAL) or mini-bronchoalveolar lavage (mini-BAL). The control species SPC (B. subtilis) was obtained as in Example 2 and the concentration added to each sample was 1.7 E4 CFU / mL. The decision threshold was 1.0 E4 CFU / mL for BAL samples and 1.0 E3 CFU / mL for mini-BAL samples.

[0119] Two cohorts of samples were collected: one training cohort of 46 samples (23 BAL samples and 23 mini-BAL samples) and one analytical cohort of 40 samples (33 BAL samples and 7 mini-BAL samples).

[0120] Culture reference measurements were performed for each target species for all samples in the training and analytical cohorts.

[0121] Samples were subjected to two rounds of lysis as described in Example 2. Sequencing was performed as described in Example 2.

[0122] For each target and control species, sequence abundance was normalized to the reads per million (RPMb) associated with the bacterial species; see step 50.

[0123] For each target species, a detection threshold DT SOIwas determined. If the results of the microbial culture of a sample were negative for the detection of the SOI in question and negative for the detection of the MetaPhlAn marker sequence specific for the SOI in question, the target species was considered not to be detected in the sample. Figure 3 shows the statistical distribution of the normalized sequence abundance in the training samples that were negative for the target species. The x-axis corresponds to each target species and the y-axis corresponds to the normalized abundance of sequences related to the target species. For each species, the median (line contained in the box), the 25th and 75th percentiles (limits of the box) were determined, allowing for representation in the form of a box diagram (or box plot). The endpoints of each vertical line correspond to the 1st and 99th percentiles. It can be seen that the distributions are significantly different from each other. This means that there is one detection threshold DT for each target species. SOI For each of the target species, a detection threshold DT SOI was determined. SOI denotes the average normalized number of sequences assigned to a target species, and σ SOI If is its standard deviation, then the detection threshold DT SOI is placed "3 sigma" above the mean according to the following formula: DT SOI = μ SOI + 3 σ SOI (3)

[0124] Detection threshold DT SPC =DT B. subtilis (associated with B. subtilis) was defined. Seven training samples without B. subtilis spike were taken into account. The mean μ B. subtilis and their standard deviations σ B. subtilis was determined. The detection threshold DT B. subtilis is as follows: DT B. subtilis = μ B. subtilis + 3 σ B. subtilis (3)

[0125] A decision threshold (SD), called the metagenomic threshold, was defined to distinguish between the normal presence of bacteria of interest and the infection of patients with these bacteria of interest. For this purpose, the results of the microbial cultures of the samples of the training cohort were divided into two separate populations as follows: The "infected" population corresponded to 20 occurrences of culture detection at concentrations above the clinical threshold, i.e. 1 in mini-BAL samples E 3 CFU / mL in BAL samples and 1 E 4 CFU / mL. The "colony forming" population corresponded to 900 occurrences of non-detection or detection by culture at concentrations below the clinical threshold, i.e., 1 E 3 CFU / mL in BAL samples and 1 E 4 CFU / mL.

[0126] In the previous two sections, the 920 occurrences corresponded to the analysis by microculture of 46 training samples performed for each of the 20 target species.

[0127] Figure 4 shows the quantification of biological species performed by culture (x-axis) and metagenomic analysis (y-axis) for various samples. In Figure 4, the filled circles correspond to species selected from Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Hafnia alvei, Klebsiella oxytoca, Klebsiella pneumoniae, Legionella pneumophila, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Stenotrophomonas maltophilia and Streptococcus pneumoniae. The open triangles correspond to Staphylococcus aureus.

[0128] Although it may not be possible to precisely correlate the concentrations in CFU / mL obtained by culture with the concentrations in GEq / mL obtained by metasequencing, as shown in Example 2 (Figure 2A), Figure 4 shows that for a target species or group of target species, "colonizing" and "infected" populations are differentiated based on the results of the quantification by sequencing (genome equivalents (GEq)). The metagenomic threshold (SD) was defined taking into account the upper percentile of the concentrations measured in the "infected" population. The value thus obtained was 5.5 E3 GEq / mL.

[0129] Therefore, it is possible to define metagenomic thresholds that form a decision threshold SD that can separate samples with a concentration of the target species located above or below the critical value based on the training samples. The critical value may correspond notably to the decision threshold SD mentioned above. The concentration of the target species determined by sequencing was then compared with its associated decision threshold. It should be noted that the decision threshold generally depends on the species in question. It is therefore possible to set one decision threshold for one species or one group of species in question. Two different species may be associated with two different decision thresholds.

[0130] Forty samples of the analytical set were sequenced. Tables 2A to 2C collate the results obtained, one for each sample 1 to 13, one for 14 to 27 and one for 28 to 40, respectively. The first row of each table contains the reference of each sample. The second row contains its associated detection threshold DT SPC represents detection (+) or non-detection (-) of the control species SPC with respect to the control species SPC. See step 60.

[0131] In samples 3, 7, 23 and 35, no control species SPCs were detected (RN SPC < DT SPC ). If the target species was not detected (RN SOI < DT SOI ) (see step 64), the result was not interpretable. This corresponds to the code INV. It was not possible to determine the concentration of the target species with respect to the decision threshold (in this case the clinical threshold) because the minimum detectable concentration was too high. If the target species was detected (RN SOI ≧ DT SOI ) (see step 62), because the control species was added at a concentration higher than the metagenomic threshold (SM) equal to 5.5 E3 GEq / mL, detection of the target species SOI was considered positive above the decision threshold, which in this example is the clinical decision threshold. This result corresponds in Tables 2A, 2B and 2C as follows: If the target species is also detected by microbial culture above the clinical threshold, then there is a true positive (TP). Alternatively, a false positive (FP or FP+) occurs when the microbiological culture does not detect the target species above the clinical threshold.

[0132] Control species were detected in samples 1, 2, 4 to 7, 8 to 22, 24 to 34, and 36 to 40 (RN SPC ≧DT SPC ). If the target species was not detected (RN SOI <DT SOI ) (see step 63), and using equation (2) to obtain the minimum detectable concentration Cmin SOI The minimum detectable concentration Cmin was set. SOI If is higher than the decision threshold SD, the results cannot be interpreted, which corresponds to the code INV in Tables 2A, 2B and 2C. SOI The detection of the target species was considered below the clinical threshold if the mean ± SD of the decision threshold (metagenomic threshold) was less than the mean ± SD of the decision threshold (metagenomic threshold). This result corresponds to the following in Tables 2A, 2B, and 2C: A false negative (FN) occurs when a target species is detected by microbial culture above the clinical threshold but quantified by metagenomic analysis below the decision threshold. · True negatives (empty box) occur when microbial culture and metagenomic analysis do not detect the target species above the clinical threshold.

[0133] Control species were detected (RN SPC ≧ DT SPC )), target species was detected (RN SOI ≧ DT SOI ), the number of sequences associated with the target species is used as a calibrator to determine the concentration of the target species, C, using equation (1) described in step 61. SOIThese results correspond to the following in Tables 2A, 2B and 2C: · A true positive (TP) is reported when the target species is detected by microbiological culture above the clinical threshold. Alternatively, a false positive (FP or FP+) result occurs when the target species is not detected by microbial culture above the clinical threshold. [Table 2A] [Table 2B] [Table 2C]

[0134] For microbial culture analysis, the decision threshold (1 E 4 CFU / mL, 1 in mini-BAL samples E Eleven occurrences with a concentration of more than 3 CFU / mL were detected. The metagenomic analysis made it possible to detect 10 of these occurrences, which correspond to the designation TP (true positive) in Tables 2A-2C. The occurrence not detected by metagenomics corresponds to E. cloacae in sample 27 and can be explained by the large amount of sequences related to E. cloacae in samples where this bacterium is absent (see Figure 3). This leads to a very high detection threshold and, consequently, a minimum detectable concentration Cmin SOI was often higher than the metagenomic threshold (SM), and this result was considered invalid for metagenomic testing (see INV in Table 2C).

[0135] The metagenomic analysis allowed the detection of 19 additional occurrences with respect to microbial culture. These occurrences are denoted as FP (false positive) or FP+ in Tables 2A-2C. Five FP+ occurrences corresponded to detections where MetaPhlAn markers and BLAST alignments (BLAST is the acronym for Basic Local Alignment Search Tool) could confirm the presence of the target species in the sample despite non-detection by culture. These complementary occurrences were probably due to a better sensitivity of the metagenomic test with respect to detection by microbial culture, allowing only the detection of viable and cultivable parts in the microbiota. The FP occurrences corresponded to false positives with too few reads associated with the target species, which could not be confirmed by the search for MetaPhlAn markers and BLAST alignments. These complementary occurrences could also be due to the high sensitivity of the metagenomic test with respect to detection by microbial culture. However, due to the lack of confirmation, a lack of specificity of the metagenomic test cannot be excluded.

[0136] The metagenomic test produced 185 invalid results - INV in Tables 2A, 2B and 2C. These results corresponded to non-detection of the target species SOI, but the minimum detection concentration Cmin SOI was higher than the metagenomic threshold (SM) and therefore could not be interpreted. This result is particularly different from the results of microbial culture, which generally give a negative result unless some device is used to independently verify the sensitivity of the detection of the bacterial species in the tested sample. Validation by metagenomic testing allowed to limit the risk of false negatives. This situation is evident from the absence of detection of E. cloacae in sample 27.

[0137] Comparison of detection results for pathogens of interest infecting patients from whom BAL and mini-BAL samples were obtained (see Table 3) clearly demonstrated the advantage of using the control species described in this invention. Detection of pathogens above the clinical decision threshold produced nearly 9 times more false positive results based directly on the normalized number of reads assigned to the target species. The use of the control species presented in this invention significantly improved the specificity of the metagenomic test, allowing better detection of infections without reducing sensitivity. [Table 3]

[0138] The specific application of the present invention to so-called shotgun sequencing is described.The present invention is also applicable to target sequences, such as so-called 16S sequences.In this case, prior to sequencing, a step of amplifying the target gene is carried out to multiply its copy in the sample.The reads used by the present invention are then the reads that correspond only to the target gene.

[0139] The use of Bacillus subtilis as a control species in metagenomic analysis of BAL or mini-BAL samples has been described. Alternatively, another control species may be used, provided that it meets all or part of the criteria described with respect to step 20. These are, for example, Bacillus stearothermophilus, Synechocystis sp. PCC6803, Pelagibacter ubique, Methanocaldococcus jannaschii, Aeropyrum pernix, Kocuria rhizophila, Azospirillum lipoferum, Lactococcus lactis, Synechococcus sp. WH 7805, Schizosaccharomyces pombe, Pantoea stewartii, Phage T4, Pichia pastoris, and Armored DNA QuantTM.

[0140] Several control species have been described that take the form of elements containing nucleic acids contained or encapsulated in a membrane (bacterial membrane, capsid, etc.). This feature is used in particular to determine whether the process of extracting nucleic acids worked as expected, with regard to the function of verifying the suitability of the metagenomic analysis. Obviously, if a biological species is used only as a calibrator, i.e. to perform only a quantification function without allowing the function of verifying suitability, the calibrator may consist of free nucleic acids added to the sample or a known amount in the DNA extract.

[0141] It has been described that the control species and the species to be calibrated are added simultaneously before the step of extracting the nucleic acid sequence. If two different biological species are used to perform the functions of compatibility and quantification (calibrators) separately, the calibrators can be added in the next step, preferably after the step of lysing the sample, to avoid the destruction of the latter if it is a question of naked nucleic acids.

[0142] The method according to the invention in particular makes it possible to assay target biological species in a sample. Preferably, in the context of a clinical application, the method according to the invention is completed by the steps of determining a course of antibiotics depending on the species identified and assayed in the sample and administering the determined course of antibiotics to the patient.

[0143] This method makes it possible to provide assistance in the diagnosis of contamination of a sample by a target species (the latter possibly being bacteria or fungi), which allows to define the appropriate treatment (antibiotic treatment in case of bacteria, antifungal treatment in case of yeasts or fungi) based on the identity of the target species and on any signs of antimicrobial resistance detected in the genome.

[0144] More generally, depending on the target application, if the concentration of a biological species is higher than a decision threshold, this is considered to indicate the occurrence of an anomaly. To rectify the anomaly, an appropriate corrective action policy is determined. For example, in the field of food processing, the target species may be bacteria. If the concentration exceeds a certain threshold, the corrective action policy may be the removal or destruction of food intended for sale and / or the cleaning of the production facility. The same is true if the process concerns a sanitary inspection to prevent nosocomial infections, for example of a facility such as part of a hospital. The recognition of the presence of an undesirable biological species leads to remedial actions such as cleanup or decontamination.

[0145] The invention may be implemented in the field of analysis of samples taken from the environment or industrial processes, for example in the food processing, pharmaceutical or cosmetic industries, to aid in diagnosis or more generally. It can also be used in hygiene testing.

Claims

1. A method for detecting a target species (SOI) potentially present in an analytical sample, said target species having a known or partially known genome, said analytical sample comprising a mixture of different species, The method comprises: a) extracting nucleic acid from said analytical sample; b) sequencing the nucleic acid sequences extracted in step a); c) Based on the results of the sequencing, (i) assigning the sequence obtained from step b) based on a sequence reference database; (ii) the amount of sequences assigned to the target species (R SOI , R.N. SOI ) is determined, (iii) the detection threshold (DT) associated with the target species; SOI ) is determined, (iv) comparing the amount obtained from substep (ii) with the detection threshold determined in substep (iii); Prior to step a), a control species is added and the control species is diluted to a known concentration (C SPC ) to the analytical sample, wherein the control species has a known genome; Step c) (v) the amount of sequence assigned to the control species (R SPC , R.N. SPC ) is determined, (vi) the detection threshold (DT) associated with said control species; SPC ) is determined, (vii) comparing the amount obtained from substep (v) with the detection threshold determined in substep (vi); d) determining the concentration of said control species (C) in response to the comparisons made in substeps (iv) and (vii); SPC ) to determine the presence of the target species in the sample. method.

2. In substeps (ii) and (v), the amounts of sequences assigned to the target species and the control species, respectively, are normalized by a reference amount. The method of claim 1.

3. determining a decision threshold (SD), step d) comprising confirming or not confirming the presence of said target species above or below said decision threshold depending on the comparisons made in substeps (iv) and (vii); The method according to claim 1 or 2.

4. The reference amount is the total number of sequences generated during the sequencing. The method according to claim 3.

5. Step d) - estimating the concentration of said target species; - or estimating the minimum concentration of the target species, determining a decision threshold (SD) and estimating the concentration of the target species relative to the decision threshold; 5. The method according to any one of claims 1 to 4.

6. In the step d), The amount of sequence assigned to the control species (RN SPC ) is the detection threshold (DT SPC ) is higher than And the amount of sequences assigned to the target species (RN SOI ) is the detection threshold (SD) associated with the target species. SOI ) is higher than Step d) involves confirming the presence of the target species in the analytical sample.

6. The method according to any one of claims 1 to 5.

7. Step d) includes estimating the concentration of the target species. The method according to claim 6.

8. adding a calibrator having a known genome at a known concentration to the analytical sample; estimating the concentration of the target species determining the amount of sequence assigned to said calibrator; determining a first ratio between the amount of sequences assigned to the target species and the calibrators, respectively; determining a second ratio between the genome size of each of the calibrators and the target species; using a concentration of said calibrator added to said analytical sample. The method of claim 7.

9. Inferring the target species includes calculating the product of the first ratio multiplied by the second ratio and the concentration of the calibrator added to the analytical sample. The method according to claim 8.

10. The control species (SPC) serves as the calibrator.

10. The method according to claim 8 or 9.

11. In step d), The amount of sequence assigned to the control species (RN SPC ) is the detection threshold (DT SPC ) is higher than And the amount of sequences assigned to the target species (RN SOI ) is the detection threshold (DT) associated with the target species. SOI ), Step d) The minimum detectable concentration (Cmin SOI ) is estimated, The minimum detectable concentration (Cmin SOI ) to a decision threshold (SD), and if the minimum detectable concentration of the target species is lower than the decision threshold, it is presumed that the target species is not present in the analytical sample at a concentration higher than the decision threshold.

6. The method according to any one of claims 3 to 5.

12. The minimum detectable concentration (Cmin SOI ) is determining a first ratio between the detection threshold of the target species and the amount of sequence assigned to the control species; determining a second ratio between the genome sizes of the control species and the target species; using a concentration of said control species added to said analytical sample The method of claim 11.

13. In step d), The amount of sequence assigned to the control species (RN SPC ) is the detection threshold (DT SPC ), And the amount of sequences assigned to the target species (RN SOI ) is the detection threshold (DT SOI ) higher, Step d) comprises comparing the concentration of the control species added to the analytical sample with the decision threshold; Step d) The concentration of the control species added to the analytical sample (C SPC ) is greater than the decision threshold (SD), confirming that the target species is present in the analytical sample at a concentration greater than the decision threshold; The concentration of the control species added to the analytical sample (C SPC confirming the presence of the target species in the analytical sample if the concentration of 6. The method according to any one of claims 3 to 5.

14. In step d), The amount of sequence assigned to the control species (RN SPC ) is the detection threshold (DT SPC ), And the amount of sequences assigned to the target species (RN SOI ) is the detection threshold (DT) associated with the target species. SOI ), The presence of the target species cannot be confirmed.

5. The method according to any one of claims 1 to 4.

15. A detection threshold (DT) associated with the target species is determined using a first number of training samples that are deemed not to contain the target species (SOI). SOI ), The method includes, for each first training sample: Extracting a nucleic acid sequence; - Sequencing the nucleic acid sequences thus extracted; determining the amount of target sequences assigned to said target species; The method comprises: Calculating a variance indicator of the amount of said target sequence determined for each first training sample; determining a detection threshold associated with the target species in response to the dispersion indicator thus calculated.

15. The method according to any one of claims 1 to 14.

16. A second plurality of training samples that are deemed not to contain the control species are used to determine a detection threshold (DT) associated with the control species. SPC ), The method further comprises: for each second training sample: Extracting a nucleic acid sequence; - Sequencing the nucleic acid sequences thus extracted; determining the amount of sequence assigned to said control species; The method comprises: calculating a variance indicator of the amount of sequences assigned to said control species and determined for each second training sample; determining a detection threshold associated with said control species in response to the dispersion indicator thus calculated.

16. The method according to any one of claims 1 to 15.

17. The second training sample is an analytical sample to which the control species is not added.

17. The method of claim 16.

18. The method according to claim 1, further comprising the steps of: determining a detection threshold value (DTSOI) associated with a target species (SOI) using a first plurality of training samples deemed not to contain the target species (SOI); The method includes, for each first training sample: Extracting the nucleic acid sequence; - Sequencing the nucleic acid sequences thus extracted; determining the amount of target sequences assigned to said target species; normalizing the amount of the target sequence assigned to the target species, The method comprises: Calculating a variance indicator of the amount of the target sequence or the normalized amount of the target sequence determined for each first training sample; determining a detection threshold associated with the target species in response to the dispersion indicator thus calculated.

16. The method according to any one of claims 1 to 15.

19. The method according to claim 19, further comprising the step of determining a detection threshold value (DTSPC) associated with said control species using a plurality of second training samples deemed not to contain said control species, The method further comprises: for each second training sample: Extracting a nucleic acid sequence; - Sequencing the nucleic acid sequences thus extracted; determining the amount of sequence assigned to said control species; normalizing the amount of sequences assigned to said control species, The method comprises: calculating a variance indicator of the amount of sequences or normalized amount of sequences determined for each second training sample assigned to said control species; determining a detection threshold associated with said control species in response to the dispersion indicator thus calculated.

16. The method according to any one of claims 1 to 15.

20. Steps c) and d) are each performed in parallel for different target species, each of which is considered to be potentially present in the sample.

20. The method of any one of claims 1 to 19.

21. Prior to step a), a plurality of said control species are added, and for a given target species, steps c) and d) are carried out with a plurality of said control species, and substeps v) to vii) are carried out in parallel for each of said control species.

21. The method according to any one of claims 1 to 20.

Citation Information

Patent Citations

  • Method of determining biospecies

    JP2007061092A

  • Method for microbiom analysis

    WO2016023991A1

  • Pathogen detection using next generation sequencing

    WO2017053446A2